Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for reducing relapse in low disease activity systemic lupus erythematosus
ChiCTR2200058379Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in systemic lupus erythematosus (SLE) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: flare rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2200058379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058379.